Literature DB >> 12052606

Contraception for women in selected circumstances.

Kathryn M Curtis1, Camaryn E Chrisman, Herbert B Peterson.   

Abstract

OBJECTIVE: To review new evidence regarding ten controversial issues in the use of contraceptive methods among women with special conditions and to present World Health Organization recommendations derived in part from this evidence. DATA SOURCES: We searched MEDLINE and PREMEDLINE databases for English-language articles, published between January 1995 and December 2001, for evidence relevant to ten key contraceptive method and condition combinations: combined oral contraceptive (OC) use among women with hypertension or headaches, combined OC use for emergency contraception and adverse events, progestogen-only contraception use among young women and among breast-feeding women, tubal sterilization among young women, hormonal contraception and intrauterine device use among women who are human immunodeficiency virus (HIV) positive, have AIDS, or are at high risk of HIV infection. Search terms included: "contraception," "contraceptives, oral," "progestational hormones," "medroxyprogesterone-17 acetate," "norethindrone," "levonorgestrel," "Norplant," "contraceptives, postcoital," "sterilization, tubal," "intrauterine devices," "hypertension," "stroke," "myocardial infarction," "thrombosis," "headache," "migraine," "adverse effects," "bone mineral density," "breast-feeding," "lactation," "age factors," "regret," and "HIV." STUDY SELECTION: From 205 articles, we identified 33 studies published in peer-reviewed journals that specifically examined risks of contraceptive use among women with pre-existing conditions. TABULATION, INTEGRATION, AND
RESULTS: Combined OC users with hypertension appear to be at increased risk of myocardial infarction and stroke relative to users without hypertension. Combined OC users with migraine appear to be at increased risk of stroke relative to nonusers with migraine. The evidence for the other eight method and condition combinations was either insufficient to draw conclusions or identified no excess risk.
CONCLUSION: Of ten contraceptive method and condition combinations assessed, the evidence supported an increased risk of cardiovascular complications with combined OC use by women with hypertension or migraine. As new evidence becomes available, assessment of risk and recommendations for use of contraceptive methods can be revised accordingly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052606     DOI: 10.1016/s0029-7844(02)01984-1

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate.

Authors:  Jarir Atthobari; Ron T Gansevoort; Sipke T Visser; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

2.  Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.

Authors:  Matt S Anderson; William D Hanley; Allison R Moreau; Bo Jin; Frederick A Bieberdorf; James T Kost; Larissa A Wenning; Julie A Stone; John A Wagner; Marian Iwamoto
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

Review 3.  Migraine in women: the role of hormones and their impact on vascular diseases.

Authors:  Simona Sacco; Silvia Ricci; Diana Degan; Antonio Carolei
Journal:  J Headache Pain       Date:  2012-02-26       Impact factor: 7.277

Review 4.  Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?

Authors:  Rossella E Nappi; Gabriele S Merki-Feld; Erica Terreno; Alice Pellegrinelli; Michele Viana
Journal:  J Headache Pain       Date:  2013-08-01       Impact factor: 7.277

5.  Use of simulated patients to evaluate combined oral contraceptive dispensing practices of community pharmacists.

Authors:  Paulo Roque Obreli-Neto; Leonardo Régis Leira Pereira; Camilo Molino Guidoni; André de Oliveira Baldoni; Srecko Marusic; Divaldo Pereira de Lyra-Júnior; Kelsen Luis de Almeida; Ana Claudia Montolezi Pazete; Janaina Dutra do Nascimento; Mitja Kos; Edmarlon Girotto; Roberto Kenji Nakamura Cuman
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

6.  Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study.

Authors:  Igor Fernando de Aquino Moreira; Maria Passos Bianchini; Gabrielle Rodrigues Campos Moreira; Alessandra Maciel Almeida; Bruno Almeida Rezende
Journal:  BMC Womens Health       Date:  2020-10-27       Impact factor: 2.809

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.